Dr. Alan Shackelford Joins Valley Agriceuticals’ Clinical Therapeutics & Research Team

Dr. Alan Shackelford Joins Valley Agriceuticals’ Clinical Therapeutics & Research Team

Shackelford is one of the world’s leading medical experts on the clinical use of cannabinoids

May 7, 2015 – New York, NY – Valley Agriceuticals, LLC, a Purchase, NY-based company dedicated to raising the industry standard for pharmaceutical-grade medical cannabis production, delivery and patient care, today announced that Dr. Alan Shackelford has joined the company’s clinical therapeutics and research team. Dr. Shackelford is one of the world’s leading experts on medical cannabis and is devoted to the study of cannabinoid medicine, clinical research and to caring for patients for whom cannabis is an effective treatment option.

Dr. Shackelford has studied the use of cannabis as a medical treatment extensively and has advised legislators in a number of U.S. states on its medical uses. He has served on the Colorado Department of Revenue Medical Marijuana Advisory Work Group and is a member of the Medical Marijuana Scientific Advisory Counsel of the Colorado Department of Public Health.

Dr. Shackelford is a graduate of the University of Heidelberg School of Medicine and completed postgraduate medical training at major teaching hospitals of the Harvard Medical School, including a residency in internal medicine and clinical Fellowships in nutritional and behavioral medicine. Dr. Shackelford also served as a research Fellow at the Harvard Medical School.

Dr. Shackelford is an outspoken proponent of the proper use of medical cannabis for patient care, and has been featured in several documentaries and news reports on the medical efficacy of cannabinoids, including reports broadcast in Australia, New Zealand and Colombia. He has also been featured in the CNN documentary series Weed: The Marijuana Revolution, hosted by Dr. Sanjay Gupta.

“Dr. Shackelford is a distinguished physician who is committed to improving patient care through the use of cannabinoids,” said Erik Holling, President of Valley Agriceuticals. “He is a natural leader who will play a major role in advancing the development of our products, research protocols, treatment guidelines, and patient care programs.”

Valley Agriceuticals is actively pursuing one of the five New York licenses for growing, cultivating and producing pharmaceutical-grade medical cannabis under New York’s New Medical Marijuana Law (Chapter 90 of the Laws of 2014.)The company intends to bring a unique, visionary approach to producing its products by incorporating best practices typically found in the pharmaceutical and biotechnology industries.

“I am excited to be joining Valley Agriceuticals and working to assist in their efforts to bring pharmaceutical-grade, standardized doses of medical cannabis to qualified patients throughout the state of New York,” said Dr. Shackelford. “Valley Agriceuticals is not only raising industry standards for developing cannabis-based products, but is also committed to delivering those products to the patients who will benefit from them through health care centers that are focused on patients’ needs.”

About Valley Agriceuticals
Valley Agriceuticals, LLC (www.valleyagriceuticals.com) is a Purchase, New York-based company comprised of leaders in science, education and medicine who are passionate about applying internationally recognized pharmaceutical and biotechnology standards to medical cannabis production and delivery. Our mission is to bring medical cannabis to qualified patients throughout the state of New York. We intend to provide pharmaceutical-grade medical cannabis to patients in need through an experienced team of healthcare and wellness professionals who will also provide patient education, counseling and support. Our vision is to set the gold standard in medical cannabis administration and patient care.

Media Contacts

Steven Greenberg
Greenberg Public Relations

Bob Bellafiore
Stanhope Partners